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Abstract
Background/Aims: Targeting survivin, an anti-apoptotic protein and mitotic regulator, is 
considered as an effective therapeutic option for pancreatic cancer (PaCa). Tolfenamic acid 
(TA) showed anti-cancer activity in pre-clinical studies. A recent discovery demonstrated a 
copper(II) complex of TA (Cu-TA) can result in higher activity. In this study, the ability of Cu-TA 
to inhibit survivin and its transcription factors, Specificity protein (Sp) 1 and 3 in PaCa cell lines 
and tumor growth in mouse xenograft model were evaluated. Methods: Cell growth inhibition 
was measured in MIA PaCa-2 and Panc1 cells for 2 days using CellTiter-Glo kit. Sp1, Sp3 and 
survivin expression (by Western blot and qPCR), apoptotic cells and cell cycle phase distribution 
(by flow cytometry) were evaluated. A pilot study was performed using athymic nude mice 
[treated with vehicle/Cu-TA (25 or 50 mg/kg) 3 times/week for 4 weeks. Results: The IC50 value 
for Cu-TA was about half than TA.Both agents repressed the protein expression of Sp1/Sp3/
survivin, Cu-TA was more effective than TA. Especially effect on survivin inhibition was 5.2 
(MIA PaCa-2) or 6.4 (Panc1) fold higher and mRNA expression of only survivin was decreased. 
Apoptotic cells increased with Cu-TA treatment in both cell lines, while Panc1 showed both 
effect on apoptosis and cell cycle (G2/M) arrest. Cu-TA decreased the tumor growth in mouse 
xenografts (25 mg/kg: 48%; 50 mg/kg: 68%). Additionally, there was no change observed in 
mice body weights, indicating no overt toxicity was occurring. Conclusion: These results show 
that Cu-TA can serve as an effective survivin inhibitor for inhibiting PaCa cell growth.
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IntroductionOver the last few decades, the cancer research community has grown immensely. Unfortunately, pancreatic cancer (PaCa) is one of the few cancers that has not made a 
significant improvement in terms of treatment and survival rates. In the U.S., PaCa is the 3rd leading cause of cancer related deaths and is one of the most fatal malignancies due to its 
poor prognosis [1-3]. PaCa diagnosis generally occurs in the late stages, after the cancer has metastasized and is aggressive in nature. There are currently no early detection methods 
for this cancer; which contributes to its late diagnosis and thus treatment is quite difficult 
[4]. Current standard treatment for PaCa include surgery and chemotherapy along with radiation. However, because of its late diagnosis, surgery is a viable option to less than 20% 
of cases [5]. Chemotherapy drugs for PaCa include gemcitabine, 5-fluorouracil, cisplatin, 
and paclitaxel [6, 7]. These cytotoxic therapies have a number of negative side effects 
including low blood count and peripheral neuropathy [8]. Certain chemotherapy drugs have additional side effects. For example, at higher dosages cisplatin can cause nerve and renal 
damage [9]. Notably, chemotherapy and radiation becomes less effective when the patient 
begins developing resistance over time [10, 11]. Thus, there is an urgent need for alternative therapies that are more effective yet less harmful.
Survivin is encoded by the BIRC5 gene and part of the inhibitor of apoptosis protein 
family [12]. Increased expression of survivin is observed during fetal development, but in 
adult cells its expression is minimal [13]. Survivin’s overexpression is considered to be a 
negative prognostic factor for patient survival [14, 15]. Satoh et al., evaluated the clinical specimens of 56 patients and survivin was found to be over-expressed in 77% of pancreatic 
ductal carcinoma patients [16]. In another study, Lee et al., found that 94% of 49 patient 
samples were positive to survivin [17]. Furthermore, survivin was shown as a constitutive 
resistance factor for radiation [18] and knocking down of survivin via siRNA technology 
attenuated radiation resistance [19]. Since the association of survivin with PaCa and the response to PaCa treatment is well established, it is ideal to exploring the agents that can target survivin and can induce anti-cancer activity.
Tolfenamic acid (TA) is classified as a non-steroidal anti-inflammatory drug (NSAID) 
and is used as a generic drug to treat migraines in Europe. Studies from our laboratory and 
others have demonstrated that TA contains anti-cancer properties such as cancer cell growth 
inhibition and induction of apoptosis in pre-clinical models, including PaCa [20-23]. Konduri 
et al. (2009) also demonstrated that TA sensitizes PaCa cells and tumors in mice (orthotopic 
model) to radiation [24]. TA has been shown to work through downregulation of Specificity 
proteins 1 and 3 (Sp1 and Sp3) [20]. They can regulate their target gene transcription by 
binding to GC-rich elements and promoter sequences. Sp1 overexpression is associated 
with tumor formation and progression, metastasis, and angiogenesis [25]. Therefore, it has 
even been suggested as a potential biomarker to detect a class of advanced pancreatic ductal 
adenocarcinoma [26].
One gene of particular interest in PaCa regulated by these Sp1 and Sp3 is survivin [27]. 
For these reasons, TA is an attractive potential chemotherapeutic for PaCa since it targets 
Sp1, Sp3, and survivin. TA has been approved for Phase I Clinical Trials along with radiation 
and gemcitabine treatment for PaCa. However, since the dosage for TA’s anti-cancer activities 
is slightly high (50 µM), strategies to enhance its efficacy is important. Therefore, we began to 
look into using a TA derivative, specifically, a metallodrug. Metal complexes have been found 
to have a synergistic activity with their original drugs which enhance the drug’s bioactivity 
[28-34]. Recently, a copper (II)-Tolfenamic acid has been synthesized and published [35]. 
We have recently evaluated the anti-proliferative activity of Cu(II)- containing complex of 
TA (Cu-TA) Cu-TA using twelve human cancer cells lines representing six cancers [36]. This 
screening study found that TA was chemically and biologically stable and demonstrated a 
higher efficacy in comparison to TA. Additionally, there was no overt toxicity observed in the 
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Cu-TA treated cardiomyocytes. In this study, we assessed the anti-cancer efficacy of Cu-TA in detail using human PaCa cell lines. The results of this study showed higher anti-cancer 
activity of Cu-TA which was accompanied by a substantially higher increase in the inhibition 
of survivin when compared to TA.
Materials and Methods
Cell lines and Culture Conditions
Two human pancreatic ductal adenocarcinoma cell lines, MIA PaCa-2 and Panc1were obtained 
American Type Culture Collection (ATCC) and authenticated using STR profiling by ATCC in July, 2018. Both 
cell lines resulted in 100% match with the ATCC database. Both cell lines were grown and cultivated in 
Dulbecco’s Modified Eagle Medium (DMEM) media with high glucose (4500 mg/L) supplemented with 5% 
fetal bovine serum and 1% penicillin streptomycin. Cells were maintained in an incubator at 37 °C with 5% CO2.
Preparation of Stock Concentrations
Tolfenamic acid was purchased from Sigma-Aldrich Corporation and a 10 mM stock solution was 
prepared in dimethyl sulfoxide (DMSO). Commercially available copper(II) chloride (CuCl2) and 2, 
2’-bipyridine (bpy) were used as controls. The copper(II)-tolfenamic acid (Cu-TA) complex was synthesized 
using an established method [35]. A 10 mM stock solution of CuCl2, BPY, and Cu-TA were all prepared in 
DMSO.
Cell Viability
MIA PaCa-2 and Panc1 cells were seeded in 96-well plates with each well containing 4, 000 cells in 
50 μl of media. 10 mM stock concentrations of each drug were diluted in 50 μl of media before treatment. 
Each treatment was carried out in triplicates with increasing concentrations of DMSO (vehicle), TA (10, 25, 
50, and 100 μM), or Cu-TA (10, 25, and 50 μM). Cells were then incubated with CellTiter-Glo reagent 24 and 
48 h post-treatment and incubated in the dark for 25 min. Cell viability was then measured by detecting 
luminescence using Synergy HT (BioTek) plate reader. For all subsequent experiments the concentration 
of Cu-TA’s IC50 value and equimolar TA were used. To test the cytotoxic effect of the components used in 
the synthesis of Cu-TA (CuCl2 and BPY), MIA PaCa-2 and Panc1 cells were treated with DMSO, CuCl2 or BPY 
using equimolar concentration of Cu-TA’s IC50 value (MIA PaCa-2: 29 μM; Panc1: 27 μM). Cell viability was measured as explained above.
Caspase 3/7 Assay
MIA PaCa-2 and Panc1 cells were seeded in 96-well plates with each well containing 4, 000 cells in 50 
μl of media. 10 mM stock concentrations of each drug were diluted in 50 μl of media before treatment, with 
each treatment done in triplicates. The activation of caspase 3 and 7 was measured using Caspase-Glo 3/7 
kit (Promega). Cells were plated in a 96-well plate and then treated with DMSO (control), Cu-TA (MIA PaCa-
2: 29 µM; Panc1: 27 µM) or equimolar TA. At 24 and 48 h, samples were incubated with Caspase 3/7-Glo 
substrate for 1 h in the dark and then read by Synergy HT (BioTek) plate reader.
Western Blot
MIA PaCa-2 and Panc1 cells were plated in 10 cm petri dishes containing 750, 000 cells in 10 ml 
of media. Cell were treated with either DMSO, Cu-TA (MIA PaCa-2: 29 µM; Panc1: 27 µM) or equimolar 
TA. After 24 and 48 h treatments, cell lysates were collected and prepared. Total cellular protein was 
extracted using cell lysis buffer and protein quantification was done using the Pierce BCA Protein Assay 
Kit (Thermo Scientific, Waltham, MA). Protein samples were then separated through 10% sodium dodecyl 
sulfate-polyacrylamide gel and then transferred to a nitrocellulose membrane. Next, the membranes were 
blocked with 5% milk in Tris-Buffered Saline with 1% Tween. Blots were incubated with primary antibody 
overnight and incubated with secondary antibody for one hour the following day. Bands were detected using 
SuperSignal West Dura Extended Duration Substrate (Thermo Scientific). Protein expression of Sp1 (Santa 
Cruz Biotechnology, Dallas, TX), Sp3 (Santa Cruz Biotechnology), cleaved PARP (Cell Signaling Technology, 
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Danvers, MA), survivin (R&D Systems, Minneapolis, MN), cyclin B1 (Cell Signaling Technology), and cyclin A 
(Cell Signaling Technology) were evaluated using specific antibodies while the expression of β-actin (Sigma-
Aldrich Corporation) was used as a loading control.
Quantitative Polymerase Chain Reaction (qPCR)
MIA PaCa-2 and Panc1 cells were plated in 10 cm petri dishes containing 750, 000 cells in 10 ml of 
media. Cells were treated with DMSO (control), Cu-TA (MIA PaCa-2: 29 µM; Panc1: 27 µM) or equimolar 
TA for 48 h. At the time of collection, total RNA was extracted from treated cells using TRIzol (Invitrogen). 
Total RNA was then converted into single-stranded cDNA using Superscript III (Invitrogen). After cDNA 
amplification, genes were probed for using TaqMan Gene Expression Assays (Applied Biosystems) and 
samples were placed in a 96-well LightCycler 96 Real-Time PCR system (Roche) for qPCR analysis. Each 
sample was done in triplicates and GAPDH was used as a housekeeping gene.
Flow cytometry
PE Annexin V Staining: Apoptotic cell populations were detected using PE Annexin V Apoptosis 
Detection Kit I (BD Biosciences). Cells were plated in 6-well plates containing 2, 000 cells in 2 ml of media. 
Cells were treated with DMSO, Cu-TA (MIA PaCa-2: 29 µM; Panc1: 27 µM) or equimolar TA for 24 and 48 h. 
Samples were collected, washed with PBS, and then incubated with Annexin V-PE/7-AAD solution for 15 
min in the dark. Apoptotic cell populations were measured via FC500 flow cytometer.
Cell Cycle Arrest
MIA PaCa-2 and Panc1 cells were plated in 6-well plates containing 2, 000 cells in 2 ml of media. Cells 
were reated with DMSO (control), Cu-TA (MIA PaCa-2: 29 µM; Panc1: 27 µM) or equimolar TA then collected 
at 24 and 48 h post-treatment. Samples were collected, washed with PBS, fixed with cold 70% ethanol and 
then stored in -80 °C overnight. The collected samples were then incubated with propidium iodide(PI)/
RNAse solution for DNA staining for 15 min at room temperature in the dark. Finally, samples were then 
incubated in 37 °C for 10 min. The cell cycle phase distribution was analyzed using FC500 Flow Cytometer.
Mouse Model
Athymic nu/nu nude mice were obtained from Charles River (Wilmington, MA). Mice were subcutaneously injected with 6 x 106 MIA PaCa-2 cells and the tumors were allowed to grow for 10 days (~100mm3 in diameter) before starting treatments. There were 3 treatment groups [vehicle (corn oil), Cu-
TA 25 mg/kg or 50 mg/kg] with 4 mice in each group (half male and half female). Mice were treated 3 times/
week for 4 weeks through oral gavage. Mouse body weights were recorded 3 times/week as well. At the 
end of 4 weeks, the mice were euthanized by CO2 asphyxiation and their tumors were harvested. The tumor volume and weights were measured and the averages in each group were calculated (n=6). The procedures 
are approved by the Institutional Animal Care and Use Committee of the University of North Texas Health 
Science Center (protocol# IACUC-2017-0040).
Statistical Analysis
Data were analyzed using one-way ANOVA. Results were expressed as mean ± SD. Significance between treated and untreated cells were evaluated, and a p value < 0.05 was considered as significant.
Results
TA and Cu-TA Inhibit PaCa Cell Growth
MIA PaCa-2 and Panc1 cells were treated with increasing concentrations of DMSO, TA 
and Cu-TA to evaluate the anti-proliferative activity and determine the optimal dosage for Cu-
TA. Both TA and Cu-TA decreased cell viability in a dose and time dependent manner in both 
MIA PaCa-2 (Fig. 1A) and Panc1 cells (Fig. 1B). However, Cu-TA was found to be more effective 
than TA for inhibiting PaCa cell growth and at lower doses. The IC50 value for Cu-TA at 48 h 
post-treatment (Fig. 1C) was found to be half (MIA PaCa-2: 29.32 μM; Panc1: 26.65 μM) that 
of TA’s IC50 value (MIA PaCa-2: 57.20 μM; Panc1: 61.76 μM). At 24 h, there was less than 50% 
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Fig. 1. Anti-proliferative effect of TA or Cu-TA against PaCa cells. MIA PaCa-2 (A) and Panc1 (B) cells were 
treated with DMSO or Cu-TA (5–50 μM) or TA (5–100 μM) and cell viability was measured after 24 and 48 
h. Lines represent % viable cells (mean ± SD) normalized to control. All treatments were done in triplicate. 
(C) IC50 values for both cell lines at 48 h for TA and Cu-TA. (D) The effect of CuCl2 and BPY on cell viability 
in MIA PaCa-2 and Panc1 cells was measured 24 and 48 h post-treatment. Bars represent % viable cells 
(mean ± SD) normalized to control. All treatments were done in triplicate, and the bars marked with ‘*’ are 
significantly different from corresponding control (p<0.0001).
Figure 1
Cell line IC50 Value TA IC50 Value Cu-TA % Less with TA
MIA PaCa-2 57.20 µM 29.32 µM 43.5
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cell growth inhibition for both cell lines. Therefore, the IC50 values were calculated only at 48 
h post-treatment and found that Cu-TA’s IC50 values were 49% and 57% less (respectively in 
MIA PaCa-2 and Panc1) when compared to TA. Additionally, neither CuCl2 nor BPY had any 
effect on cell viability (Fig. 1D).
Cu-TA Downregulates Sp1, Sp3 and Survivin Protein Expression
The effect of Cu-TA on Sp1, Sp3 and survivin protein expression was assessed via 
Western blot.  There was a significant inhibition of Sp1, Sp3 and survivin protein expression 
with the Cu-TA 48 h treatment in both cell lines (Fig. 2A&B). TA is known to downregulate 
Sp1, Sp3 and survivin protein expression, however, at the equimolar dosage of Cu-TA’s IC50 value there was no change.
Fig. 2. Effect of Cu-TA on Sp1, Sp3 and survivin expression in PaCa cells. (A&B) MIA PaCa-2 and Panc1 cells 
were treated with DMSO, Cu-TA (MIA PaCa-2: 29 µM; Panc1: 27 µM) or equimolar TA for 24 and 48 h. Protein 
extracts from cell lysates were then prepared and the expression of Sp1, Sp3, survivin, and β-actin (loading 
control) was determined by Western blot analysis. All experiments were conducted with 3 sets of samples 
and the representative gels are shown in the Figure. (C&D) MIA PaCa-2 and Panc1 cells were treated with 
DMSO or Cu-TA (MIA PaCa-2: 29 µM; Panc1: 27 µM) or equimolar TA for 48 h. Total RNA was then extracted 
and mRNA expression levels of Sp1, Sp3 and survivin were assessed via qPCR. GAPDH was used as a 
housekeeping gene. Bars represent mRNA fold change (mean ± SD) normalized to control. All treatments 
were done in triplicates, and the bars marked with ‘*’ are significantly different from corresponding control (P<0.001).
Figure 2
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TA and Cu-TA Lower Survivin mRNA Expression Levels While Sp1 and Sp3 Remains 
Unaltered
Quantitative PCR results demonstrate that TA and Cu-TA treatments significantly lower 
survivin mRNA expression levels in both cell lines (Fig. 2C&D). This indicates that survivin is 
effected at the transcriptional level. However, Sp1 and Sp3 mRNA expression levels remain relatively unchanged in both cell lines.
Cu-TA Increases Apoptotic Markers and Apoptotic Cell Populations
Cells were treated with Cu-TA or TA and their effect on effector caspase 3/7 activity, 
protein expression of c-PARP and apoptotic cell populations were analyzed. Cu-TA treated 
cells had a significant increase in effector caspase 3/7 activity and this correlated with an 
increase in c-PARP expression (Fig. 3). A significant increase in apoptotic cell populations 
was also observed for the Cu-TA treatment (Fig. 4).
Cu-TA Causes G2/M Phase Arrest in Panc1 Cells
Cu-TA’s effect on cell cycle phase distribution was determined by flow cytometric 
analysis. Cu-TA had no effect on MIA PaCa-2 cells (Fig. 5A), while there was an increase in 
G2/M phase in Panc1 cells (Fig. 5B; Fig. 6A) at 48 h. Confirmation of G2/M phase arrest was 
done by examining protein expression of G2/M markers, cyclin B1 and cyclin A (Fig. 6B).
Fig. 3. Cu-TA upregulates effector caspase activity, cleaved PARP expression, and apoptotic cell populations 
in PaCa cells. (A) MIA PaCa-2 and Panc1 cells were treated with DMSO, Cu-TA (MIA PaCa-2: 29 µM; Panc1: 
27 µM) or equimolar TA. Caspase 3/7 activity and c-PARP protein expression was determined at 24 and 48 
h post-treatment. (B) shows the fold change of apoptotic cell populations in MIA PaCa-2 and Panc1. Bars 
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Fig. 4. Cu-TA increases apoptotic cell populations in PaCa cells. (A) MIA PaCa-2 and (B) Panc1 cells were 
treated with DMSO, Cu-TA (MIA PaCa-2: 29 µM; Panc1: 27 µM) or equimolar TA. Apoptotic cell populations 
were assessed using PE Annexin V Staining post 24 and 48 h treatment.
Figure 4
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Fig. 5. Cu-TA causes G2/M phase arrest in Panc1 cells. (A) MIA PaCa-2 and (B) Panc1 cells were treated with 
DMSO, Cu-TA (MIA PaCa-2: 29 µM; Panc1: 27 µM) or equimolar TA for 24 and 48 h post-treatment. Cells 
were collected and then incubated with propidium iodide DNA staining. Samples were then analyzed via 
flow cytometry. Peaks indicate respective phase (G0, S, G2/M) of the cell cycle.
Figure 5
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Cu-TA Dose Dependently 
Inhibits Tumor Growth 
in PaCa Mouse Model
Both Cu-TA treatment groups caused a decrease in tumor weights and volume which appears to be a dose dependent response. The 
Cu-TA 25mg/kg group had a 48% decrease while the 
50 mg/kg group had a 68% decrease in tumor weight 
(Fig. 7A). Tumor volume also showed similar trend 
showing 39% (25 mg/kg 
group) and 73% decrease 
(50 mg/kg group) decrease when compared to control 
group (Fig. 7B). In addition, there was a decrease in tumor vasculature as 
pictured (insert) in Fig. 7A. There was no change in mice body weights (Fig. 7C), indicating no overt toxicity.
DiscussionThe limited treatment options and therapy effectiveness pose a crucial need for novel treatments for PaCa. for their 
transformation and subsequent progression and resistance to radiation/chemotherapy [37]. 
Resistance to current therapeutic options is a major barrier in PaCa treatment. Therefore, an effective approach for treatment could be targeting the molecular mechanisms that drive 
tumorigenesis and resistance. In this study, we were particularly interested in survivin 
because of its known role in poor prognosis and resistance to treatment in PaCa. Due to morbidity associated with standard care, it is not plausible to increase the doses when the patients show poor response, thereby treatment of such patients is becoming even more challenging. Therefore, the strategies to identify less toxic agents to induce sensitivity in 
cancer cells and the therapeutic efficacy is our top priority. There have been an increasing 
Fig. 6. Confirmation of G2/M phase arrest 
in Panc1 cells. (A) Panc1 cells were treated 
with DMSO, Cu-TA (27 µM) or equimolar 
TA for 48 h. Cells were collected and then 
incubated with propidium iodide DNA 
staining. Samples were then analyzed via 
flow cytometry. Bars represent % cells in 
a particular cell cycle phase (mean ± SD) 
normalized to control. All treatments were 
done in triplicate, and the bars marked 
with ‘*’ are significantly different from 


































Fig. 7. Cu-TA inhibits PaCa tumor growth in mouse: Athymic nude mice 
were injected with 6 million MIA PaCa-2 cells and were treated with 
either vehicle (corn oil), Cu-TA 25 mg/kg or 50 mg/kg 3 times/week 
for 4 weeks. Mean (±SE) of (A) tumor weight and (B) tumor volume (representative tumor pictures in the insert) of the mice treated with 
vehicle or 25 mg/kg of Cu-TA or 50 mg/kg of Cu-TA (n=6 per group). 
(C) The body weights were measured each week and the weight 
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number of studies using NSAIDs as chemopreventive and chemotherapeutic agents [38], 
because NSAIDs are not only effective, but also less toxic in comparison to conventional 
chemotherapy drugs [39]. Several strategies including small molecules for inhibiting cell 
growth pathways have been tested [40, 41] . NSAIDs are small molecules that typically work 
by inhibiting cyclooxygenase (COX) enzymes and thereby modulating prostaglandins [42]. 
However, there are limitations to the use of NSAIDs for cancer therapy especially the issues 
associated with long-term use [43]. Therefore, there has been rising interest in finding 
NSAIDs that work independent of COX enzyme inhibition.
Our laboratory and others have demonstrated the effectiveness of TA (NSAID) for 
inhibiting PaCa cell growth in cancer models [20, 24, 44]. In this study, the cell viability 
results demonstrated that Cu-TA’s anti-proliferative effect in PaCa cells is much more effective 
resulting the IC50 value about 50% less than TA in both cell lines (Fig. 1A&B). Furthermore, neither CuCl2 nor BPY had any significant effect on cell growth in either cell line at 24 and 
48 h post-treatment (Fig. 1C). This demonstrates that the decrease in cell viability is specific 
to the Cu-TA compound and not to any single agent alone. Protein analysis showed that Cu-
TA treatment caused downregulation of Sp1, Sp3 and survivin (Fig. 2A&B). To investigate if this downregulation was due to the targets being effected on a transcriptional level or 
post-translationally, mRNA levels were examined. Survivin was found to be significantly 
downregulated on a transcriptional level while both Sp1 and Sp3 levels were comparatively 
unaffected (Fig. 2C&D) suggesting that significant decrease of survivin mRNA levels could 
be due to a lack of Sp1- and Sp3-dependent transcription [27]. These results correspond 
with previous TA data; TA is known to effect Sp1 and Sp3 post-translationally, through 
proteasome-dependent degradation [24]. This suggests that Cu-TA perhaps work in a similar 
mechanism to TA.
To investigate the cause of growth inhibitory response seen in the Cu-TA treatment, 
the apoptotic markers, caspase 3/7 and c-PARP and the number of apoptotic cells were 
evaluated. Thus, the increased caspase 3/7 activity and protein expression of c-PARP in the 
Cu-TA treatment suggests that the activation of apoptosis is occurring (Fig. 3A). Annexin-V 
has a high affinity for PS, thus, when linked to the fluorochrome phycoerythrin (PE), it is 
possible to detect apoptotic cell populations via flow cytometry [45]. Annexin-V flow 
cytometric results showed Cu-TA significantly increased apoptotic cell populations (Fig. 3A; 
Fig. 4), correlating with the increased caspase activity and cleaved PARP expression (Fig. 
3A).
Cell cycle phase distribution was also examined. The Cu-TA treatment in Panc1 cells 
revealed an increase in G2/M phase cells compared to the control, indicating cell cycle arrest 
(Fig. 5B; Fig. 6A). Cell cycle is a highly regulated process involving a series of events that leads to faithful replication of cells. The transition and progression of cell cycle phase depends on 
differential expression of various cyclins [46]. Cyclins form complexes with their respective 
cyclin-dependent kinases (CDKs) which can then regulate transcription of target genes [47]. 
The expression of cyclin A and B1 were evaluated because of their function and accumulation 
in G2/M phase transition [48, 49]. Downregulation of both cyclins confirmed cell cycle arrest 
results. This G2/M phase arrest caused by Cu-TA may be partially responsible for the growth 
inhibitory response in Panc1 cells. There was no cell cycle arrest observed in MIA PaCa-2 
cells at either time point studied. Cu-TA could perhaps be predominantly affecting apoptotic 
pathways rather than cell cycle arrest in MIA PaCa-2 cells. Next Generation Sequencing analysis is currently under investigation to understand what other pathways are affected by 
Cu-TA treatment.
Because of our successful results in the in vitro assays, a pilot study using a mouse model 
for PaCa was done to confirm our findings in an in vivo model. The Cu-TA treatment dose 
dependently caused a decrease in tumor weights (25mg/kg: 48%; 50 mg/kg: 68%) (Fig. 7A). 
Apart from the reduction in tumor size and weight, there is also a visible decrease in tumor 
vasculature (Fig. 7A). This is significant since tumor vasculature is vital for tumor growth 
and survival [50]. Furthermore, there was no changes observed in the mice body weights 
(Fig. 7B), indicating that no obvious toxicity was occurring with Cu-TA treatment.
In summary, Cu-TA’s IC50 dosage to inhibit cell proliferation was found to be half that of 
TA demonstrating higher efficacy and the growth inhibitory effect of Cu-TA was attributed 
to cell cycle arrest; demonstrated by an increase of Panc1 cells in G2/M phase. Activation 
of apoptosis was also shown (by increasing effector caspase activity, cleaved PARP 
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protein expression and apoptotic cell populations) and may contribute to the inhibition of 
proliferation. Molecular regulators that drive tumorigenesis and resistance, Sp1 and Sp3, 
were downregulated with Cu-TA. Expression of one of their targets, survivin, was also found 
to be significantly decreased. While we see a trend in inhibition of Sp1 and Sp3, the most 
responsive marker is survivin, with MIA PaCa-2 having 82.8% protein inhibition and Panc1 
86.7% (Fig. 2A&B). This further supports that the anti-cancer activity seen with Cu-TA 
may be more associated with survivin. In the TA treatment, Sp1, Sp3 and survivin protein 
expression are all relatively unaffected. However, in the Cu-TA treatment, the effect is higher 
in survivin when compared to Sp1 and Sp3. Cu-TA was found to have a significant increase in 
survivin inhibition (MIA PaCa-2: 5.2-fold; Panc1: 6.4-fold) compared to TA. Both Sp1 and Sp3 
regulate survivin and can inhibit or activate its expression. If the downregulation of survivin 
is through Sp proteins inhibition (post-translational degradation), then the effect observed is an additive response. However, other mechanisms could be involved and pathway analysis 
of Cu-TA treatment in PaCa cells is currently under investigation.
Conclusion
In conclusion, survivin is a tangible marker to target for treating cancers due to its strong 
association with tumorigenesis and resistance to therapy and the specific agents to target 
survivin are still under investigation. In this investigation, Cu-TA showed anti-cancer activity 
in PaCa cells and had an enhanced efficacy in comparison to TA via inhibiting survivin. 
Finding a potent inhibitor of survivin for PaCa treatment is just as vital as finding a non-toxic and stable agent. The growth inhibitor effect seen in our in vitro studies were reproducible 
in our mouse model for PaCa. Recent findings from our group [36] demonstrated the stable biological (anti-proliferative activity against PaCa cells) and structural stability as 
characterization by FTIR and UV-visible spectroscopy for up to 12 months. Additionally, Cu-
TA did not cause any significant cytotoxicity in cardiomyocytes [36]. The cardiomyocyte data 
along with our mouse model results provides preliminary evidence that Cu-TA is non-toxic to 
non-malignant cells. The ultimate goal of investigating Cu-TA would be to use this alongside 
standard treatment care. By downregulating survivin, we hope to sensitize the cancer cells to treatment. Therefore, allowing the patients to receive less chemotherapy and radiation for 
less side effects without compromising therapeutic efficacy. Further testing is required, but 
this provides preliminary evidence for the potential use of Cu-TA in PaCa treatment.
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